Search
Flecainide
go.drugbank.com/drugs/DB01195ApprovedInvestigationalWithdrawn[A186880] Flecainide’s development began in 1966 and was first synthesized in 1972 as an attempt to generate new anesthetics. … [A186931] It is used to prevent supraventricular and ventricular arrhythmias, as well as paroxysmal atrial fibrillation and flutter.
Pariglasgene brecaparvovec
go.drugbank.com/drugs/DB16801ApprovedPariglasgene brecaparvovec-opnr is an adeno-associated virus serotype 8 (AAV8)–based gene therapy for glycogen storage disease type Ia (GSDIa), a disorder caused by deficiency of the enzyme glucose-6-phosphatase … [L64050] Restoring hepatic G6Pase activity supports the release of glucose during fasting, and in clinical studies reduced patients' reliance on dietary cornstarch used to prevent hypoglycemia.
Lansoprazole
go.drugbank.com/drugs/DB00448ApprovedInvestigationalalong with other pathologies caused by excessive acid secretion. … [A177065] It reduces gastric acid secretion by targeting gastric H,K-ATPase pumps and is thus effective at promoting healing in ulcerative diseases, and treating gastroesophageal reflux disease (GERD)
Nirogacestat
go.drugbank.com/drugs/DB12005ApprovedInvestigationalbe 41% compared to 8% with the placebo. … Desmoid tumors are typically characterized by aberrant activation in Notch signaling.
4-Hydroxytestosterone
go.drugbank.com/drugs/DB01485IllicitInvestigationalIt is specifically the 17-hydroxylated analog to formestane. … [A14385] Like formestane, 4-hydroxytesterone has been patented for use in decreasing estrogen production in the body, but no such indication currently exists. 4-Hydroxytestosterone was first patented in
Elranatamab
go.drugbank.com/drugs/DB15395ApprovedInvestigationallight chain to drug structure. … [L47820] Elranatamab was also approved by the European Commission on December 8, 2023.[L50437]
Categories: Bispecific B-cell maturation antigen (BCMA)-directed CD3 T-cell engagerSynonyms: IMMUNOGLOBULIN G2-KAPPA, ANTI-(HOMO SAPIENS T-CELL SURFACE GLYCOPROTEIN CD3 EPSILON CHAIN CD3E (T-CELL SURFACE ANTIGEN T3/LEU-4 EPSILON CHAIN)), HUMAN-MUS MUSCULUS MONOCLONAL DISULFIDE WITH IMMUNOGLOBULINAmlexanox
go.drugbank.com/drugs/DB01025ApprovedWithdrawnRecurrent aphthous ulcer (RAU) is the most prevalent oral mucosal disease in humans, estimated to affect between 5% and 50% of the general population.
Nicoboxil
go.drugbank.com/drugs/DB12911ApprovedWithdrawnnicoboxil/nonivamide topical analgesic medication being used since the 1950s, recent studies demonstrate continued interest in the medication(s) given its demonstrated efficacy, safety, and capability to … be used as an alternative musculoskeletal pain therapy option with less systemic side effects when compared to the oral non-steroidal anti-inflammatory drugs and opioids that may be more typically prescribed
Vismodegib
go.drugbank.com/drugs/DB08828ApprovedInvestigationalVismodegib is an orally active small molecule that inhibits the hedgehog signaling pathway by binding to and inhibiting the transmembrane protein smoothened homologue (SMO). … In July 2013, it was approved by the EMA, and since then, it has been approved by several other countries.[A7370,A258618,L45803]
Muromonab
go.drugbank.com/drugs/DB00075ApprovedInvestigationalWithdrawnMurine monoclonal antibody specific to CD3 T-cell lymphocyte antigens. … More specifically it is a purified murine (mouse) monoclonal antibody, directed against the CD3 (T3) receptor on the surface of human T-cells (T-lymphocytes) cultured using the murine ascites method.